cabozantinib,atezolizumab
roche
['cosmic-021', '#gu,(-#gui),(-#gunagratinib),(-#guard),(-#gut)']
 cosmic-021 study , variant histology, cohort 10 , 31% orr #gu23 
Instructor of Medicine, Harvard Medical School. GU-oncologist at Lank Center for Genitourinary Oncology, Dana-Farber Cancer Institute. #conquercancer